Skip to main content
Premium Trial:

Request an Annual Quote

Matthew Tindall

Omicia has tapped Matthew Tindall to be its CEO effective immediately. Tindal also joins the company's board of directors. Prior to joining Omicia, he served as general manager of IMS Health's Consumer Solutions division. Before that, he held positions with Celera Genomics, Genzyme Corporation, and Digitas Health.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.